The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome
Open accessAbstract
HBV infection remains a leading cause of death worldwide. IFN-α inhibits viral replication in vitro and in vivo, and pegylated IFN-α is a commonly administered treatment for individuals infected with HBV. The HBV genome contains a typical IFN-stimulated response element (ISRE), but the molecular mechanisms by which IFN-α suppresses HBV replication have not been established in relevant experimental systems. Here, we show that IFN-α inhibits HBV replication by decreasing the transcription of pregenomic RNA (pgRNA) and subgenomic RNA from the HBV covalently closed circular DNA (cccDNA) minichromosome, both in cultured cells in which HBV is replicating and in mice whose livers have been repopulated with human hepatocytes and infected with HBV. Administration of IFN-α resulted in cccDNA-bound histone hypoacetylation as well as active recruitment to the cccDNA of transcriptional corepressors. IFN-α treatment also reduced binding of the STAT1 and STAT2 transcription factors to active cccDNA. The inhibitory activity of IFN-α was linked to the IRSE, as IRSE-mutant HBV transcribed less pgRNA and could not be repressed by IFN-α treatment. Our results identify a molecular mechanism whereby IFN-α mediates epigenetic repression of HBV cccDNA transcriptional activity, which may assist in the development of novel effective therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interferon-inducible antiviral effectors
Sadler, A. J., & Williams, B. R. G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2314 · Cited by 2,160
EASL clinical practice guidelines management of chronic hepatitis B
张学武, & Li, X. (2009) · Inter J Epidemiol Infect Dis · doi:10.3760/cma.j.issn.1673-4149.2009.04.001 · Cited by 1,506
Robertson, G., Hirst, M., Bainbridge, M., Bilenky, M., Zhao, Y., Zeng, T., Euskirchen, G., Bernier, B., Varhol, R., Delaney, A., et al. (2007) · Nature Methods · doi:10.1038/nmeth1068 · Cited by 1,454
EASL Clinical Practice Guidelines: Management of chronic hepatitis B
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.10.001 · Cited by 1,347
Transcription factor YY1: structure, function, and therapeutic implications in cancer biology
Gordon, S., Akopyan, G., Garban, H., & Bonavida, B. (2006) · Oncogene · doi:10.1038/sj.onc.1209080 · Cited by 756
Caretti, G., Di Padova, M., Micales, B., Lyons, G. E., & Sartorelli, V. (2004) · Genes & Development · doi:10.1101/gad.1241904 · Cited by 600
Control of cccDNA function in hepatitis B virus infection
Levrero, M., Pollicino, T., Petersen, J., Belloni, L., Raimondo, G., & Dandri, M. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.05.022 · Cited by 552
Günther, S., Li, B. C., Miska, S., Krüger, D. H., Meisel, H., & Will, H. (1995) · Journal of Virology · doi:10.1128/jvi.69.9.5437-5444.1995 · Cited by 499
Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function
Belloni, L., Pollicino, T., De Nicola, F., Guerrieri, F., Raffa, G., Fanciulli, M., Raimondo, G., & Levrero, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908365106 · Cited by 498
Self-citationHepatitis B virus X protein is essential to initiate and maintain virus replication after infection
Lucifora, J., Arzberger, S., Durantel, D., Belloni, L., Strubin, M., Levrero, M., Zoulim, F., Hantz, O., & Protzer, U. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.015 · Cited by 481
Self-citation
Cited by
Shared and Distinct Functions of Type I and Type III Interferons
Lazear, H. M., Schoggins, J. W., & Diamond, M. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.025 · Cited by 1,138
Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA
Lucifora, J., Xia, Y., Reisinger, F., Zhang, K., Stadler, D., Cheng, X., Sprinzl, M. F., Koppensteiner, H., Makowska, Z., Volz, T., et al. (2014) · Science · doi:10.1126/science.1243462 · Cited by 893
Self-citationTherapeutic strategies for hepatitis B virus infection: towards a cure
Fanning, G. C., Zoulim, F., Hou, J., & Bertoletti, A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0037-0 · Cited by 557
A global scientific strategy to cure hepatitis B
Revill, P. A., Chisari, F. V., Block, J. M., Dandri, M., Gehring, A. J., Guo, H., Hu, J., Kramvis, A., Lampertico, P., Janssen, H. L. A., et al. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30119-0 · Cited by 508
Self-citationHepatitis B virus biology and life cycle
Tsukuda, S., & Watashi, K. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104925 · Cited by 376
Cornberg, M., Lok, A. S.-F., Terrault, N. A., Zoulim, F., Berg, T., Brunetto, M. R., Buchholz, S., Buti, M., Chan, H. L. Y., Chang, K.-M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.11.003 · Cited by 366
Self-citationHepatitis B cure: From discovery to regulatory approval
Lok, A. S., Zoulim, F., Dusheiko, G., & Ghany, M. G. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.008 · Cited by 344
Present and future therapies of hepatitis B: From discovery to cure
Liang, T. J., Block, T. M., McMahon, B. J., Ghany, M. G., Urban, S., Guo, J., Locarnini, S., Zoulim, F., Chang, K., & Lok, A. S. (2015) · Hepatology · doi:10.1002/hep.28025 · Cited by 317
Hepatitis B cure: From discovery to regulatory approval
Lok, A. S., Zoulim, F., Dusheiko, G., & Ghany, M. G. (2017) · Hepatology · doi:10.1002/hep.29323 · Cited by 303
Hepatitis B flares in chronic hepatitis B: Pathogenesis, natural course, and management
Chang, M.-L., & Liaw, Y.-F. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.08.033 · Cited by 296
Gish, R. G., Given, B. D., Lai, C.-L., Locarnini, S. A., Lau, J. Y. N., Lewis, D. L., & Schluep, T. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.06.008 · Cited by 259
Zeisel, M. B., Lucifora, J., Mason, W. S., Sureau, C., Beck, J., Levrero, M., Kann, M., Knolle, P. A., Benkirane, M., Durantel, D., et al. (2015) · Gut · doi:10.1136/gutjnl-2014-308943 · Cited by 256
Self-citation3D microfluidic liver cultures as a physiological preclinical tool for hepatitis B virus infection
Ortega-Prieto, A. M., Skelton, J. K., Wai, S. N., Large, E., Lussignol, M., Vizcay-Barrena, G., Hughes, D., Fleck, R. A., Thursz, M., Catanese, M. T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02969-8 · Cited by 236
Mak, L.-Y., Wong, D. K.-H., Pollicino, T., Raimondo, G., Hollinger, F. B., & Yuen, M.-F. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.05.042 · Cited by 223
Self-citationChen, J., Zhang, W., Lin, J., Wang, F., Wu, M., Chen, C., Zheng, Y., Peng, X., Li, J., & Yuan, Z. (2014) · Molecular Therapy · doi:10.1038/mt.2013.212 · Cited by 159
Cytokine-Mediated Immunopathogenesis of Hepatitis B Virus Infections
Li, X., Liu, X., Tian, L., & Chen, Y. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-014-8465-4 · Cited by 104
Hepatitis B virus receptors and molecular drug targets
Verrier, E. R., Colpitts, C. C., Sureau, C., & Baumert, T. F. (2016) · Hepatology International · doi:10.1007/s12072-016-9718-5 · Cited by 25
Metadata
- Authors
- Belloni, L., Allweiss, L., Guerrieri, F., Pediconi, N., Volz, T., Pollicino, T., Petersen, J., Raimondo, G., Dandri, M., & Levrero, M.
- Venue
- Journal of Clinical Investigation
- Published
- 2012-02-01
- Volume
- 122
- Issue
- 2
- Pages
- 529-537
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2015763479
- Cited by
- 577
- References
- 30
- FWCI
- 28.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.